A clinical trial to determine if AIC263029 is safe when dosed only once or several times, and to investigate how it moves within the human body

2023-510074-13-00 Protocol AIC468-01-I-01 Human pharmacology (Phase I) - First administration to humans Ended

Start 2 Oct 2024 · End 16 Mar 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol AIC468-01-I-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 104
Countries 1
Sites 1

BKV-associated nephropathy

Key facts

Sponsor
AiCuris Anti-infective Cures AG
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Virus Diseases [C02]
Trial duration
2 Oct 2024 → 16 Mar 2026
Decision date (initial)
2024-03-15
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

BKV-associated nephropathy

VersionLevelCodeTermSystem organ class
20.0 HLGT 10047438 Viral infectious disorders 10021881
20.1 LLT 10065333 BK virus nephropathy 10021881
20.1 PT 10065381 Polyomavirus-associated nephropathy 100000004862
20.0 HLT 10057200 Polyomavirus infections 10021881
20.0 SOC 10021881 Infections and infestations 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

AiCuris Anti-infective Cures AG

Sponsor organisation
AiCuris Anti-infective Cures AG
Address
Friedrich-Ebert-Strasse 475, Elberfeld West Elberfeld West
City
Wuppertal
Postcode
42117
Country
Germany

Scientific contact point

Organisation
AiCuris Anti-infective Cures AG
Contact name
Dirk Kropeit

Public contact point

Organisation
AiCuris Anti-infective Cures AG
Contact name
Information Desk

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 104 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
CRS Clinical Research Services Management GmbH
Medical Director, Siemensdamm 65, Siemensstadt, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-10-02 2026-03-16 2024-10-07 2025-11-21

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-12-19 Germany Acceptable
2024-03-13
2024-03-15
2 SUBSTANTIAL MODIFICATION SM-1 2024-07-29 Germany Acceptable
2024-08-22
2024-08-22
3 SUBSTANTIAL MODIFICATION SM-3 2024-10-29 Germany Acceptable
2024-11-25
2024-11-26
4 SUBSTANTIAL MODIFICATION SM-4 2024-12-19 Germany Acceptable
2025-01-13
2025-01-14
5 SUBSTANTIAL MODIFICATION SM-5 2025-04-07 Germany Acceptable
2025-04-24
2025-04-24
6 SUBSTANTIAL MODIFICATION SM-6 2025-09-08 Germany Acceptable
2025-10-08
2025-10-10